

Leishmaniasis treatment using Triazole-phthalimides as chemotherapeutic agents

Problema

The different clinical forms of leishmaniasis (cutaneous, mucocutaneous, and visceral) share a common treatment approach involving toxic chemotherapy and serious side effects, leading to the development of treatment resistance. Thus, the search for more specific drugs against parasites, without causing harm to the host, is still needed.

Solução

The technology relies on the use of molecules containing the compounds triazole and phthalimide, obtained through a cheap and high-yield method, as leishmanicidal agents for the treatment of leishmaniasis. The combination of molecules with different modes of action into a single chemical entity can reduce the side effects and the emergence of resistance, observed in conventional medications against leishmaniasis.


Diferencial

Diminuição toxicidade

Less chance of developing resistance

Cheap and efficient synthesis

Estágio de Desenvolvimento



O que buscamos?

Partners to advance through the stages of pre-clinical and clinical studies of the technology and in obtaining the molecule on a large scale.

[WANT MORE INFORMATION? CONTACT US!](#)

Inventores

Regina Celia Bressan Queiroz de Figueiredo

Propriedade Intelectual

Tipo
Patente de Invenção

Descrição
Patent application submitted in Brazil.

[VER PATENTE](#)

GESTEC

SISTEMA
GESTEC-NIT

Use your phone camera to scan the QR Code:



Campus Fiocruz Maré - Av. Brasil, 4036 - Maré, Rio de Janeiro - RJ

CEP: 21040-361

portfolio@fiocruz.br

+55 (21) 3282-9080